NVO:NYE-Novo Nordisk A/S (USD)

EQUITY | Drug Manufacturers - General | New York Stock Exchange

Last Closing

USD 87.37

Change

0.00 (0.00)%

Market Cap

USD 81.07B

Volume

6.06M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

N/A

USD 690.46B
JNJ Johnson & Johnson

N/A

USD 347.83B
ABBV AbbVie Inc

N/A

USD 310.27B
PFE Pfizer Inc

N/A

USD 145.81B
BMY Bristol-Myers Squibb Company

N/A

USD 116.28B
OGN Organon & Co

N/A

USD 3.94B
GSK GlaxoSmithKline PLC ADR

N/A

N/A
MRK Merck & Company Inc

N/A

N/A
NVS Novartis AG ADR

N/A

N/A

ETFs Containing NVO

OZEM Roundhill GLP-1 & Weight .. 18.00 % 0.00 %

N/A

USD 0.04B
THNR Amplify ETF Trust 13.43 % 0.00 %

N/A

USD 4.36M
TTTX:CA Global X Innovative Bluec.. 8.97 % 0.00 %

N/A

CAD 5.03M
PPH VanEck Pharmaceutical ETF 6.72 % 0.36 %

N/A

USD 0.60B
LIFE-B:CA Evolve Global Healthcare .. 5.27 % 0.00 %

N/A

N/A
BELT BlackRock Long-Term U.S. .. 5.19 % 0.00 %

N/A

USD 0.01B
PJIO PGIM ETF Trust 5.15 % 0.00 %

N/A

USD 0.01B
QLTI The 2023 ETF Series Trust.. 4.01 % 0.00 %

N/A

USD 4.63M
MEDI Harbor Health Care ETF 3.33 % 0.00 %

N/A

USD 0.02B
GINX SGI Enhanced Global Incom.. 3.16 % 0.00 %

N/A

N/A
ULTY Tidal Trust II 2.72 % 0.00 %

N/A

USD 0.29B
SPWO SP Funds Trust 2.59 % 0.00 %

N/A

USD 0.03B
APIE Trust For Professional Ma.. 1.45 % 0.00 %

N/A

USD 0.79B
AVSD American Century ETF Trus.. 1.30 % 0.00 %

N/A

USD 0.15B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

N/A

USD 0.81B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

N/A

N/A
RFAP 0.00 % 0.83 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
PTIN Pacer Trendpilot Internat.. 0.00 % 0.00 %

N/A

USD 0.14B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

N/A

USD 0.44B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
BKIE BNY Mellon International .. 0.00 % 0.00 %

N/A

USD 0.75B
GINN Goldman Sachs Innovate Eq.. 0.00 % 0.00 %

N/A

USD 0.28B
LEAD-U:CA 0.00 % 0.00 %

N/A

N/A
LEAD:CA Evolve Future Leadership .. 0.00 % 0.00 %

N/A

CAD 0.02B
LEAD-B:CA Evolve Future Leadership .. 0.00 % 0.00 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.54% 10% F 15% F
Dividend Return 1.39% 20% F 23% F
Total Return -14.15% 10% F 14% F
Trailing 12 Months  
Capital Gain -15.54% 10% F 15% F
Dividend Return 1.39% 20% F 23% F
Total Return -14.15% 10% F 14% F
Trailing 5 Years  
Capital Gain 202.68% 89% A- 95% A
Dividend Return 16.26% 44% F 54% F
Total Return 218.94% 89% A- 95% A
Average Annual (5 Year Horizon)  
Capital Gain 37.14% 90% A- 90% A-
Dividend Return 38.77% 90% A- 90% A-
Total Return 1.63% 20% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 34.82% 10% F 30% F
Risk Adjusted Return 111.34% 80% B- 98% N/A
Market Capitalization 81.07B 86% B+ 100% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.90 57% 26%
Price/Book Ratio 22.27 43% 4%
Price / Cash Flow Ratio 3.34 100% 67%
Price/Free Cash Flow Ratio 24.08 43% 13%
Management Effectiveness  
Return on Equity 88.73% 100% 99%
Return on Invested Capital 70.15% 100% 98%
Return on Assets 21.47% 100% 99%
Debt to Equity Ratio 14.99% 86% 84%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.